End-of-day quote
Shanghai S.E.
06:00:00 2024-07-11 pm EDT
|
5-day change
|
1st Jan Change
|
4.12
CNY
|
-0.72%
|
|
0.00%
|
-44.92%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
6,871
|
6,592
|
4,534
|
3,261
|
3,072
|
Enterprise Value (EV)
1 |
6,213
|
6,005
|
4,066
|
2,903
|
2,866
|
P/E ratio
|
79.9
x
|
51.9
x
|
40.9
x
|
52.9
x
|
93.5
x
|
Yield
|
0.48%
|
0.62%
|
-
|
1.01%
|
0.47%
|
Capitalization / Revenue
|
27.1
x
|
19.5
x
|
12.6
x
|
9.92
x
|
10.2
x
|
EV / Revenue
|
24.5
x
|
17.8
x
|
11.3
x
|
8.83
x
|
9.5
x
|
EV / EBITDA
|
70
x
|
41.2
x
|
26.4
x
|
23.4
x
|
31.6
x
|
EV / FCF
|
-58
x
|
-49.4
x
|
-32.2
x
|
-29.4
x
|
-25.3
x
|
FCF Yield
|
-1.73%
|
-2.03%
|
-3.11%
|
-3.4%
|
-3.95%
|
Price to Book
|
5.36
x
|
4.72
x
|
2.83
x
|
2.18
x
|
2.06
x
|
Nbr of stocks (in thousands)
|
409,700
|
409,700
|
410,644
|
410,644
|
410,644
|
Reference price
2 |
16.77
|
16.09
|
11.04
|
7.940
|
7.480
|
Announcement Date
|
4/23/20
|
4/25/21
|
4/26/23
|
4/26/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
275.1
|
253.8
|
337.7
|
358.4
|
328.6
|
301.5
|
EBITDA
1 |
103.5
|
88.78
|
145.6
|
153.9
|
124.3
|
90.67
|
EBIT
1 |
91.61
|
73.82
|
124.9
|
110.3
|
67.56
|
27.7
|
Operating Margin
|
33.3%
|
29.08%
|
36.98%
|
30.77%
|
20.56%
|
9.19%
|
Earnings before Tax (EBT)
1 |
101.3
|
90.84
|
150
|
126
|
74.55
|
36.27
|
Net income
1 |
87.58
|
77.96
|
129.5
|
110.2
|
61.1
|
31.52
|
Net margin
|
31.83%
|
30.71%
|
38.35%
|
30.75%
|
18.59%
|
10.45%
|
EPS
2 |
0.2600
|
0.2100
|
0.3100
|
0.2700
|
0.1500
|
0.0800
|
Free Cash Flow
1 |
51.37
|
-107.2
|
-121.6
|
-126.3
|
-98.76
|
-113.1
|
FCF margin
|
18.67%
|
-42.23%
|
-36.01%
|
-35.25%
|
-30.06%
|
-37.51%
|
FCF Conversion (EBITDA)
|
49.63%
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
58.66%
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0800
|
0.0800
|
0.1000
|
-
|
0.0800
|
0.0350
|
Announcement Date
|
8/9/19
|
4/23/20
|
4/25/21
|
4/26/23
|
4/26/23
|
4/26/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
354
|
658
|
587
|
468
|
357
|
206
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
51.4
|
-107
|
-122
|
-126
|
-98.8
|
-113
|
ROE (net income / shareholders' equity)
|
12.7%
|
7.38%
|
9.66%
|
7.28%
|
4.11%
|
1.99%
|
ROA (Net income/ Total Assets)
|
6.72%
|
3.75%
|
5.27%
|
4.43%
|
2.64%
|
1.08%
|
Assets
1 |
1,304
|
2,079
|
2,458
|
2,488
|
2,318
|
2,912
|
Book Value Per Share
2 |
2.310
|
3.130
|
3.410
|
3.900
|
3.650
|
3.630
|
Cash Flow per Share
2 |
1.070
|
0.3800
|
0.2800
|
0.1200
|
0.1300
|
0.1100
|
Capex
1 |
78.8
|
104
|
164
|
188
|
93.1
|
130
|
Capex / Sales
|
28.64%
|
41.01%
|
48.43%
|
52.5%
|
28.34%
|
43%
|
Announcement Date
|
8/9/19
|
4/23/20
|
4/25/21
|
4/26/23
|
4/26/23
|
4/26/24
|
|
1st Jan change
|
Capi.
|
---|
| -44.92% | 233M | | -9.29% | 81.7B | | -7.35% | 6.82B | | +33.75% | 3.96B | | +19.93% | 1.76B | | -4.00% | 1.27B | | -37.88% | 1.03B | | -42.33% | 963M | | -19.10% | 846M | | -35.67% | 840M |
Veterinary Drugs
|